SAN FRANCISCO, Aug. 30, 2018 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a commercial-stage
biopharmaceutical company focused on saving and improving the lives
of pets, will participate in the LD Micro San Francisco Summit
taking place September 4th, the CL
King 16th Annual Best Ideas Conference and the Lake Street Capital
Markets 2nd Annual Best Ideas Growth Conference, both taking place
September 13th in New York.
During this time, investors will have the opportunity to discuss
recent developments, including the launch of KindredBio's first
product, key therapeutic programs in development, and upcoming
milestones.
Conference Details:
LD Micro San Francisco Summit
Date: Tuesday, September 4,
2018
KindredBio participant: Richard
Chin, M.D., President and Chief Executive Officer
Presentation time: 12:30 PM PT
Location: JW Marriott Union Square, SF
CL King 16th Annual Best Ideas Conference
Date: Thursday, September 13,
2018
KindredBio participant: Richard
Chin, M.D., President and Chief Executive Officer
Presentation time: 8:00 - 8:35 AM
ET
Location: Omni Berkshire Place Hotel, NY, Rockefeller
Webcast URL: Click here
An archived version of the above webcast will be available for
30 days on the Company's website.
Lake Street Capital Markets 2nd Annual Best Ideas Growth
Conference
Date: Thursday, September 13,
2018
KindredBio participant: Katja
Buhrer, VP Corporate Development and Investor Relations
Location: Parker New York
Important Safety Information
Mirataz® (mirtazapine
transdermal ointment) is for topical use in cats only under
veterinary supervision. Do not use in cats with a known
hypersensitivity to mirtazapine or any of the excipients or in cats
treated with monoamine oxidase inhibitors (MAOIs). Not for human
use. Keep out of reach of children. Wear gloves to apply and wash
hands after. Avoid contact with treated cat for 2 hours following
application. The most common adverse reactions include
application site reactions, behavioral abnormalities (vocalization
and hyperactivity) and vomiting. Please see the full Prescribing
Information.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company
focused on saving and improving the lives of pets. Its mission is
to bring to pets the same kinds of safe and effective medicines
that human family members enjoy. The Company's strategy is to
identify compounds and targets that have already demonstrated
safety and efficacy in humans and to develop therapeutics based on
these validated compounds and targets for dogs, cats and horses.
The Company has a deep pipeline of novel drugs and biologics in
development across many therapeutic classes. KindredBio's first
approved drug is Mirataz® (mirtazapine transdermal ointment) for
the management of weight loss in cats.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with
KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content with
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-participate-in-the-cl-king-16th-annual-best-ideas-conference-lake-street-capital-markets-2nd-annual-best-ideas-growth-conference-and-ld-micro-san-francisco-summit-300704636.html
SOURCE Kindred Biosciences, Inc.